The Impact of Respiratory Syncytial Virus Disease Prevention on Pediatric Asthma

Caballero, Mauricio T.; Jones, Marcus Herbert; Karron, Ruth A.; Hartert, Tina V.; Simões, Eric A F; Stein, Renato T.; Wairagkar, Niteen; Polack, Fernando P.

doi:10.1097/inf.0000000000001167

Cited by 17 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that RSV infections in early life may augment type 2 responses in the lung that persist into later life and predispose to the development of AAD and asthma. Together, with clinical association studies, these findings indicate the potential for developing and testing RSV‐targeted strategies for wheeze in infancy and the subsequent development of asthma, particularly in children with a family history of asthma and atopy …”

Section: Infections and Severe Steroid‐resistant Allergic Airway Dismentioning

confidence: 76%

“…Together, with clinical association studies, these findings indicate the potential for developing and testing RSV-targeted strategies for wheeze in infancy and the subsequent development of asthma, particularly in children with a family history of asthma and atopy. 85 In addition to the role of virus infections in early life, increasing evidence supports a role for Chlamydia respiratory infections in the development of asthma. Chlamydia respiratory infections are a primary cause of pneumonia in early life.…”

Section: Early Life Infections and The Development Of Severe Aad Anmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms and treatments for severe, steroid‐resistant allergic airway disease and asthma

Hansbro

Kim

Starkey

et al. 2017

Immunological Reviews

115

114

View full text Add to dashboard Cite

Severe, steroid-resistant asthma is clinically and economically important since affected individuals do not respond to mainstay corticosteroid treatments for asthma. Patients with this disease experience more frequent exacerbations of asthma, are more likely to be hospitalized, and have a poorer quality of life. Effective therapies are urgently required, however, their development has been hampered by a lack of understanding of the pathological processes that underpin disease. A major obstacle to understanding the processes that drive severe, steroid-resistant asthma is that the several endotypes of the disease have been described that are characterized by different inflammatory and immunological phenotypes. This heterogeneity makes pinpointing processes that drive disease difficult in humans. Clinical studies strongly associate specific respiratory infections with severe, steroid-resistant asthma. In this review, we discuss key findings from our studies where we describe the development of representative experimental models to improve our understanding of the links between infection and severe, steroid-resistant forms of this disease. We also discuss their use in elucidating the mechanisms, and their potential for developing effective therapeutic strategies, for severe, steroid-resistant asthma. Finally, we highlight how the immune mechanisms and therapeutic targets we have identified may be applicable to obesity-or pollution-associated asthma.

show abstract

Section: Infections and Severe Steroid‐resistant Allergic Airway Dismentioning

confidence: 76%

Section: Early Life Infections and The Development Of Severe Aad Anmentioning

confidence: 99%

Mechanisms and treatments for severe, steroid‐resistant allergic airway disease and asthma

Hansbro

Kim

Starkey

et al. 2017

Immunological Reviews

115

114

View full text Add to dashboard Cite

show abstract

“…In recent years, a group of investigators elaborated guidelines for the evaluation of recurrent wheezing and asthma in ongoing vaccine and monoclonal antibody studies [ 81 ]. Yet, we must remain mindful that asthma is a set of heterogeneous diseases sharing a set of common symptoms.…”

Section: Probe Studies Exploring Causalitymentioning

confidence: 99%

A Durable Relationship: Respiratory Syncytial Virus Bronchiolitis and Asthma past Their Golden Anniversary

2020

Self Cite

View full text Add to dashboard Cite

Numerous preventive strategies against respiratory syncytial virus (RSV) are undergoing late stage evaluation in humans and, in addition to their intended benefit for acute illness, may impact long term consequences of infection in infants. Severe RSV infection has been repeatedly associated in the literature with long term complications, including impaired lung function, recurrent wheezing, and asthma. However, whether RSV lower respiratory tract infection (LRTI) causally affects the odds for developing wheezing and/or asthma during childhood requires further study, and the biological mechanisms underlying this hypothetical progression from viral illness to chronic lung disease are poorly characterized. In this review, we summarize the literature exploring the association between RSV LRTI in infancy and subsequent recurrent wheezing and pediatric asthma.

show abstract

“…Novel antiviral strategies are being studied in hospitalized patients . Numerous multicenter collaborations advance to clarify the role of the pathogen in long term morbidity (ie,: asthma) and infant mortality . Recent reports are describing the consequences of infection in pregnant women .…”

Section: The Futurementioning

confidence: 99%

“…33 Numerous multicenter collaborations advance to clarify the role of the pathogen in long term morbidity (ie,: asthma) and infant mortality. 8,9,34,35 Recent reports are describing the consequences of infection in pregnant women. 3,36 Recently, Shi et al 8 estimated that a successful maternal or newborn immunization strategy, with 80% protection and near universal coverage, could prevent 22 000 RSV-associated fatalities a year.…”

Section: The Futurementioning

confidence: 99%

Respiratory syncytial virus is an “opportunistic” killer

Caballero

Polack

2018

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV), responsible for more than three million yearly hospitalizations and up to 118 000 deaths in children under 5 years, is the leading pulmonary cause of death for this age group that lacks a licensed vaccine. Ninety‐nine percent of deaths due to the virus occur in developing countries. In‐hospital RSV fatalities affect previously healthy term infants in association with bacterial sepsis, clinically significant pneumothoraxes and, to a lesser extent, comorbid conditions. Community deaths affect low‐income children from socially vulnerable families and appear to be as frequent as inpatient fatalities. In industrialized countries, RSV deaths occur almost exclusively in children with premorbid conditions.In a sense, RSV is an “opportunistic” killer. It needs a synergistic premorbid, medical practice‐related, infectious, or social co‐factor to cause a fatal outcome. But while the complex problems associated with these co‐factors await solutions, candidate vaccines, long‐lived monoclonal antibodies and antivirals against RSV are under clinical evaluation. It seems reasonable to predict that the landscape of RSV infections will look different in the next decade.

show abstract

The Impact of Respiratory Syncytial Virus Disease Prevention on Pediatric Asthma

Cited by 17 publications

References 10 publications

Mechanisms and treatments for severe, steroid‐resistant allergic airway disease and asthma

Mechanisms and treatments for severe, steroid‐resistant allergic airway disease and asthma

A Durable Relationship: Respiratory Syncytial Virus Bronchiolitis and Asthma past Their Golden Anniversary

Respiratory syncytial virus is an “opportunistic” killer

Contact Info

Product

Resources

About